Morphew, Emilie

Morphew, Emilie was paid $203K by Medicaid between Jan 2018 and Dec 2022, across 34 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 21% of everything it billed.

Compared with peers

Next to other Cytopathology Physician providers in Indiana

Rank by total paid#3 of 6

Median peer was paid$51K

This provider vs. median4.0×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	2,790	$14K
2019	4,425	$19K
2020	9,557	$57K
2021	10,045	$64K
2022	7,819	$48K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	21%	1,063	970	$42K
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	15%	873	821	$31K
80053	Comprehensive metabolic panel	14%	5,476	3,937	$28K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	11%	7,693	4,274	$22K
84484		5.8%	2,226	1,610	$12K
80048	Basic metabolic panel (calcium, ionized)	5.6%	2,714	1,065	$11K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	4.3%	414	360	$9K
83735		4.3%	2,492	1,191	$9K
83690		2.5%	1,541	1,289	$5K
87804	Infectious agent antigen detection by immunoassay; Influenza, each type	2.1%	270	253	$4K
81001		1.8%	2,195	1,900	$4K
81025		1.8%	1,818	1,594	$4K

22 more codes

87040		1.4%	221	$3K
85730		1.3%	747	$3K
85610		1.1%	1,192	$2K
83605		1.1%	413	$2K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	<1%	113	$2K
83880		<1%	198	$2K
87086	Culture, bacterial; quantitative colony count, urine	<1%	367	$2K
85027		<1%	452	$1K
87430		<1%	125	$933.52
82248		<1%	509	$876.08
81003		<1%	632	$663.54
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	26	$595.40
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	26	$595.40
85379		<1%	122	$457.50
83036	Hemoglobin; glycosylated (A1C)	<1%	126	$375.58
86901		<1%	160	$368.95
87641		<1%	13	$297.83
86900		<1%	160	$274.75
87081		<1%	74	$208.56
84105		<1%	111	$195.44
86850		<1%	56	$158.11
87186		<1%	18	$118.65

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.